$1.75 -0.08 (%) Coronado Biosciences Inc - NASDAQ

Sep. 16, 2014 | 04:00 PM

Partner Headlines

  1. Morning Market Movers

    Benzinga | Dec. 13, 2013 | 10:02AM EST
  2. Coronado Releases Interim Data; Says Final Results of Study Expected Mid 2014

    Benzinga | Dec. 12, 2013 | 16:34PM EST
  3. Coronado Biosciences Announces Independent Data Monitoring Committee Recommends Discontinuing Falk Phase 2 Trial of TSO in Crohn's Disease

    Benzinga | Nov. 7, 2013 | 06:38AM EST
  4. UPDATE: Canaccord Genuity Downgrades Coronado Biosciences Following TRUST-1 Trial Miss

    Benzinga | Oct. 15, 2013 | 09:12AM EST
  5. TheStreetSweeper Says Warned Investors about Coronado Biosciences Months Ago

    Benzinga | Oct. 14, 2013 | 21:43PM EST
  6. Morning Market Losers

    Benzinga | Oct. 14, 2013 | 10:12AM EST
  7. UPDATE: Coronado Says Top-Line Results from Trust-I Phase 2 Trial of TSO for Crohn's Did Not Meet Primary Endpoint

    Benzinga | Oct. 14, 2013 | 08:32AM EST
  8. Coronado Reports Initiation of Phase 2 Study Evaluating TSO in Ulcerative Colitis

    Benzinga | Sep. 12, 2013 | 07:33AM EST
  9. Weekly CFO Buys Highlight

    GuruFocus | Jul. 28, 2013 | 19:52PM EST
  10. Weekly CEO Buys Highlight: CNDO

    GuruFocus | Jan. 21, 2013 | 06:12AM EST
  11. Coronado Biosciences New CEO Makes First Buy of the Year, Worth $114K

    GuruFocus | Jan. 16, 2013 | 11:09AM EST
  12. Coronado Biosciences Inc (CNDO) CEO Harlan F Weisman buys 20,000 Shares

    GuruFocus | Jan. 15, 2013 | 12:36PM EST
  13. UPDATE: Wedbush Securities Initiates Coronado Biosciences at Outperform on Outlook for CNDO-201

    Benzinga | Dec. 20, 2012 | 06:06AM EST
  14. Coronado Biosciences Inc. (CNDO) CEO Bobby W Phd Sandage buys 3,811 Shares

    GuruFocus | Dec. 4, 2012 | 08:33AM EST
  15. Coronado Biosciences Inc (CNDO) CEO Bobby W Phd Sandage buys 3,811 Shares

    GuruFocus | Dec. 3, 2012 | 11:37AM EST
  16. Coronado Initiates Phase 1/2 Dose Escalation Trial of Allogeneic Natural Killer Cells Activated by CNDO-109

    Benzinga | Nov. 28, 2012 | 00:45AM EST
  17. Weekly CEO Buys Highlight: SXL, JBSS, GNMK, CNDO, DCO

    GuruFocus | Jun. 30, 2012 | 08:28AM EST
  18. Coronado Biosciences Announces Closing of $28.8 Million Public Offering

    Benzinga | Jun. 27, 2012 | 11:13AM EST
  19. Coronado Biosciences Announces the Pricing of Public Offering of 5M Shares at $5.00

    Benzinga | Jun. 22, 2012 | 01:51AM EST
  20. Coronado Biosciences Receives Orphan-Drug Designation From FDA for CNDO-109-Activated Allogeneic Natural Killer Cells for the Treatment of AML

    Benzinga | Jun. 19, 2012 | 04:35AM EST
  21. Financial Breakfast: Morning News Summary for June 8, 2012

    Benzinga | Jun. 8, 2012 | 01:32AM EST
  22. A Peek Into The Market Before The Trading Starts

    Benzinga | Jun. 8, 2012 | 01:24AM EST
  23. Coronado Biosciences Receives Notice of Allowance for First U.S. Patent Covering CNDO-109

    Benzinga | Jun. 8, 2012 | 01:00AM EST
  24. Financial Breakfast: Morning News Summary for February 14, 2012

    Benzinga | Feb. 14, 2012 | 01:18AM EST
  25. Coronado Biosciences Announces IND Submission for CNDO-109 for the Treatment of Relapsed Acute Myeloid Leukemia

    Benzinga | Feb. 14, 2012 | 00:10AM EST
  26. Coronado Biosciences Signs Binding Terms of Agreement to Enter Into Collaboration for Development of CNDO-201

    Benzinga | Dec. 22, 2011 | 07:00AM EST
Trading Center